Moberg Pharma AB (publ) (STO: MOB)

Market Cap	1.50B
Revenue (ttm)	4.93M
Net Income (ttm)	-22.75M
Shares Out	46.69M
EPS (ttm)	-0.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,503
Open	31.92
Previous Close	31.72
Day's Range	31.60 - 32.46
52-Week Range	6.15 - 40.90
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Moberg Pharma AB

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 9
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MOB

Financial Performance

In 2023, TRAIN.B's revenue was 166.32 million, an increase of 14.67% compared to the previous year's 145.04 million. Earnings were 36.92 million, a decrease of -68.36%.